A Phase I Study of Lintuzumab-Ac225 in Patients With Refractory Multiple Myeloma
Clinical trial NCT02998047 · TERMINATED
Trial details
- NCT number
- NCT02998047
- Sponsor
- Actinium Pharmaceuticals
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2020-05-01
- Enrollment
- 2
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.